Canadian hereditary angioedema guideline
department or school: Medicine, Department of
department or school: Medicine, Faculty of
department or school: Non UBC
data provider: DSpace
identifier citation: Allergy, Asthma & Clinical Immunology. 2014 Oct 24;10(1):50
rights copyright: Betschel et al.; licensee BioMed Central Ltd.
creator: Betschel, Stephen
creator: Badiou, Jacquie
creator: Binkley, Karen
creator: Hébert, Jacques
creator: Kanani, Amin
creator: Keith, Paul
creator: Lacuesta, Gina
creator: Yang, Bill
creator: Aygören-Pürsün, Emel
creator: Bernstein, Jonathan
creator: Bork, Konrad
creator: Caballero, Teresa
creator: Cicardi, Marco
creator: Craig, Timothy
creator: Farkas, Henriette
creator: Longhurst, Hilary
creator: Zuraw, Bruce
creator: Boysen, Henrik
creator: Borici-Mazi, Rozita
creator: Bowen, Tom
creator: Dallas, Karen
creator: Dean, John
creator: Lang-Robertson, Kelly
creator: Laramée, Benoît
creator: Leith, Eric
creator: Mace, Sean
creator: McCusker, Christine
creator: Moote, Bill
creator: Poon, Man-Chiu
creator: Ritchie, Bruce
creator: Stark, Donald
creator: Sussman, Gordon
creator: Waserman, Susan
issued: 2015-11-05T03:19:25
issued: 2014-10-24
description: Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries where there are more organized models for HAE management, and where additional therapeutic options are licensed and available for use. The objective of this guideline is to provide graded recommendations for the management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their advocates, that there will be an improved understanding of the current recommendations regarding management of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/55169
note: POSITION ARTICLE AND GUIDELINES Open AccessCanadian hereditary angioStephen Betschel1*, Jacquie Badiou2, Karen Binkley1, Jacques Hébert3, Amin Kanani4, Paul Keith5, Gina Lacuesta6,Bill Yang7, Emel Aygören-Pürsün8, Jonathan Bernstein9, Konrad Bork10, Teresa Caballero11, Marco Cicardi12,Timothy Craig13, Henriette Farkas14, Hilary Longhurst15, Bruce Zuraw16, Henrik Boysen17, Rozita Borici-Mazi18,Tom Bowen19, Karen Dallas20, John Dean21, Kelly Lang-Robertson1, Benoît Laramée22, Eric Leith23, Sean Mace1,Christine McCusker24, Bill Moote25, Man-Chiu Poon26, Bruce Ritchie27, Donald Stark4, Gordon Sussman1and Susan Waserman5ALLERGY, ASTHMA & CLINICAL IMMUNOLOGYBetschel et al. Allergy, Asthma & Clinical Immunology 2014, 10:50http://www.aacijournal.com/content/10/1/501University of Toronto, Toronto, Ontario, CanadaFull list of author information is available at the end of the article* Correspondence: betschels@smh.caAbstractHereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks ofpainful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks areassociated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the caseof laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The careof patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countrieswhere there are more organized models for HAE management, and where additional therapeutic options arelicensed and available for use. The objective of this guideline is to provide graded recommendations for themanagement of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis,long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, andcomprehensive care. It is anticipated that by providing this guideline to careg…
has type: Article
is shown at: 10.14288/1.0220529
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: BioMed Central
publisher DOI: 10.1186/1710-1492-10-50
rights: Attribution 4.0 International (CC BY 4.0)
rights URI: http://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
subject: Hereditary angioedema
subject: Guideline
subject: Recommendations
subject: Acute attacks
subject: Short-term prophylaxis
subject: Long-term prophylaxis
subject: Self-administration
subject: Individualized therapy
subject: Quality of life
subject: Comprehensive care
subject: GRADE
type: Text
identifier URI: http://hdl.handle.net/2429/55169